Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 15, Issue 2, 2016, Pages e9-e15

  Wong, Hui Li ^a,b   Lee, Belinda ^a,b,c   Field, Kathryn ^b   Lomax, Anna ^d   Tacey, Mark ^b   Shapiro, Jeremy ^e,f   McKendrick, Joe ^d   Zimet, Allan ^g   Yip, Desmond ^h   Nott, Louise ⁱ   Jennens, Ross ^g   Richardson, Gary ^e   Tie, Jeanne ^a,b,j   Kosmider, Suzanne ^j   Parente, Phillip ^d   Lim, Lionel ^d,k   Cooray, Prasad ^d   Tran, Ben ^a,b   Desai, Jayesh ^b   Wong, Rachel ^a,d,f   Gibbs, Peter ^a,b,c,j   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d EASTERN HEALTH   (Australia)

^e CABRINI INSTITUTE   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g EPWORTH HOSPITAL   (Australia)

^h Canberra and Calvary Hospitals ^*  (Australia)

ⁱ ROYAL HOBART HOSPITAL   (Australia)

^j WESTERN HEALTH   (Australia)

^k Ringwood Private Hospital   (Australia)

more..

Author keywords

Anti VEGF therapy; Bowel cancer; Distal colorectal cancer; Personalized medicine; Proximal colorectal cancer

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUSTRALIAN; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CECUM; COLON; COLON CANCER; COLON DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECTUM CANCER; RECTUM DISEASE; SIGMOID; SPLEEN; SURVIVAL RATE; TRANSVERSE COLON; TUMOR INVASION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; REGISTER; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84960968937     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.02.007     Document Type: Article

References (25)

1. S. Ogino, A.T. Chan, C.S. Fuchs, and et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field Gut 60 2011 397 411
2. S.D. Markowitz, and M.M. Bertagnolli Molecular origins of cancer: molecular basis of colorectal cancer N Engl J Med 361 2009 2449 2460
3. J.A. Bufill Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location Ann Intern Med 113 1990 779 788
4. O. Delattre, S. Olschwang, D.J. Law, and et al. Multiple genetic alterations in distal and proximal colorectal cancer Lancet 2 1989 353 356
5. M. Yamauchi, T. Morikawa, A. Kuchiba, and et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum Gut 61 2012 847 854
6. F. Benedix, F. Meyer, R. Kube, and et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma Pathol Res Pract 208 2012 592 597
7. T.J. Price, C. Beeke, S. Ullah, and et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer 121 2015 830 835
8. M.K. Maus, D.L. Hanna, C.L. Stephens, and et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy Pharmacogenomics J 15 2015 354 362
9. T. Sugai, W. Habano, Y.F. Jiao, and et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas J Mol Diagn 8 2006 193 201
10. F. Benedix, U. Schmidt, P. Mroczkowski, and et al. Colon carcinoma - classification into right and left sided cancer or according to colonic subsite? Analysis of 29,568 patients Eur J Surg Oncol 37 2011 134 139
11. E. Missiaglia, B. Jacobs, G. D'Ario, and et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features Ann Oncol 25 2014 1995 2001
12. G.H. Lee, G. Malietzis, A. Askari, and et al. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review Eur J Surg Oncol 41 2015 300 308
13. R.A. Meguid, M.B. Slidell, C.L. Wolfgang, and et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 15 2008 2388 2394
14. S.Y. Brule, D.J. Jonker, C.S. Karapetis, and et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 Eur J Cancer 51 2015 1405 1414
15. J.C. von Einem, V. Heinemann, L.F. von Weikersthal, and et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial J Cancer Res Clin Oncol 140 2014 1607 1614
16. M.K. Boisen, J.S. Johansen, C. Dehlendorff, and et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer Ann Oncol 24 2013 2554 2559
17. F. Loupakis, D. Yang, L. Yau, and et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer J Natl Cancer Inst 107 2015
18. K. Field, J. Shapiro, H.L. Wong, and et al. Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice Intern Med J 45 2015 267 274
19. F. Sclafani, and D. Cunningham Cetuximab or bevacizumab in metastatic colorectal cancer? Lancet Oncol 15 2014 1040 1041
20. N.B. Volz, S. Stintzing, W. Zhang, and et al. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer Pharmacogenomics J 15 2015 69 76
21. V. Formica, R. Palmirotta, G. Del Monte, and et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab Int J Colorectal Dis 26 2011 143 151
22. T.F. Hansen, R. Christensen, R.F. Andersen, and et al. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial Int J Colorectal Dis 27 2012 715 720
23. S.D. Zhang, C.M. McCrudden, C. Meng, and et al. The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab Onco Targets Ther 8 2015 835 843
24. P. Ulivi, E. Scarpi, A. Passardi, and et al. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial J Transl Med 13 2015 258
25. G. Pentheroudakis, V. Kotoula, E. Fountzilas, and et al. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG) BMC Cancer 14 2014 111